<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2023//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_230101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">35034773</PMID><DateCompleted><Year>2022</Year><Month>04</Month><Day>07</Day></DateCompleted><DateRevised><Year>2023</Year><Month>03</Month><Day>02</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1878-108X</ISSN><JournalIssue CitedMedium="Internet"><Volume>45</Volume><Issue>3</Issue><PubDate><Year>2022</Year><Month>Mar</Month></PubDate></JournalIssue><Title>Trends in neurosciences</Title><ISOAbbreviation>Trends Neurosci</ISOAbbreviation></Journal><ArticleTitle>Lysosomal dysfunction in neurodegeneration: emerging concepts and methods.</ArticleTitle><Pagination><StartPage>184</StartPage><EndPage>199</EndPage><MedlinePgn>184-199</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1016/j.tins.2021.12.004</ELocationID><ELocationID EIdType="pii" ValidYN="Y">S0166-2236(21)00252-6</ELocationID><Abstract><AbstractText>The understanding of lysosomes has come a long way since the initial discovery of their role in degrading cellular waste. The lysosome is now recognized as a highly dynamic organelle positioned at the crossroads of cell signaling, transcription, and metabolism. Underscoring its importance is the observation that, in addition to rare monogenic lysosomal storage disorders, genes regulating lysosomal function are implicated in common sporadic neurodegenerative diseases, including Alzheimer's disease (AD), Parkinson's disease (PD), and amyotrophic lateral sclerosis (ALS). Developing therapies for these disorders is particularly challenging, largely due to gaps in knowledge of the underlying molecular and cellular processes. In this review, we discuss technological advances that have propelled deeper understanding of the lysosome in neurodegeneration, from elucidating the functions of lysosome-related disease risk variants at the level of the organelle, cell, and tissue, to the development of disease-specific biological models that recapitulate disease manifestations. Finally, we identify key questions to be addressed to successfully bridge the gap to the clinic.</AbstractText><CopyrightInformation>Published by Elsevier Ltd.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Udayar</LastName><ForeName>Vinod</ForeName><Initials>V</Initials><AffiliationInfo><Affiliation>Roche Pharmaceutical Research and Early Development, Neuroscience and Rare Diseases Discovery &amp; Translational Area, Roche Innovation Center Basel, F. Hoffmann-La Roche Ltd., Basel, Switzerland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Chen</LastName><ForeName>Yu</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Medical Genetics Branch, National Human Genome Research Institute, National Institutes of Health, Bethesda, MD, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sidransky</LastName><ForeName>Ellen</ForeName><Initials>E</Initials><AffiliationInfo><Affiliation>Medical Genetics Branch, National Human Genome Research Institute, National Institutes of Health, Bethesda, MD, USA. Electronic address: sidranse@mail.nih.gov.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Jagasia</LastName><ForeName>Ravi</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Roche Pharmaceutical Research and Early Development, Neuroscience and Rare Diseases Discovery &amp; Translational Area, Roche Innovation Center Basel, F. Hoffmann-La Roche Ltd., Basel, Switzerland. Electronic address: ravi.jagasia@roche.com.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>Z99 HG999999</GrantID><Acronym>ImNIH</Acronym><Agency>Intramural NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D052060">Research Support, N.I.H., Intramural</PublicationType><PublicationType UI="D016454">Review</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2022</Year><Month>01</Month><Day>13</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Trends Neurosci</MedlineTA><NlmUniqueID>7808616</NlmUniqueID><ISSNLinking>0166-2236</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000544" MajorTopicYN="Y">Alzheimer Disease</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000690" MajorTopicYN="Y">Amyotrophic Lateral Sclerosis</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008247" MajorTopicYN="N">Lysosomes</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D010300" MajorTopicYN="Y">Parkinson Disease</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Alzheimer&#x2019;s disease</Keyword><Keyword MajorTopicYN="N">Parkinson&#x2019;s disease</Keyword><Keyword MajorTopicYN="N">amyotrophic lateral sclerosis</Keyword><Keyword MajorTopicYN="N">frontotemporal dementia</Keyword><Keyword MajorTopicYN="N">lysosomes</Keyword></KeywordList><CoiStatement>Declaration of interests V.U. and R.J. are employed by F. Hoffmann-La Roche. The Sidransky laboratory has received funding from the Michael J. Fox Foundation, the Aligning Science Across Parkinson&#x2019;s Initiative, and from F. Hoffmann-La Roche under a Cooperative Research and Development Agreement with the National Human Genome Research Institute and the National Center for Advancing Translational Sciences.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2021</Year><Month>5</Month><Day>13</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2021</Year><Month>11</Month><Day>23</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2021</Year><Month>12</Month><Day>12</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2022</Year><Month>1</Month><Day>18</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2022</Year><Month>4</Month><Day>8</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2022</Year><Month>1</Month><Day>17</Day><Hour>5</Hour><Minute>37</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">35034773</ArticleId><ArticleId IdType="mid">NIHMS1772403</ArticleId><ArticleId IdType="pmc">PMC8854344</ArticleId><ArticleId IdType="doi">10.1016/j.tins.2021.12.004</ArticleId><ArticleId IdType="pii">S0166-2236(21)00252-6</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Settembre C et al. (2013) Signals for the lysosome: a control center for cellular clearance and energy metabolism. Nat Rev Mol Cell Biol. 14, 283&#x2013;296</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4387238</ArticleId><ArticleId IdType="pubmed">23609508</ArticleId></ArticleIdList></Reference><Reference><Citation>Lawrence RE and Zoncu R (2019) The lysosome as a cellular centre for signalling, metabolism and quality control. Nat. Cell Biol 21, 133&#x2013;142</Citation><ArticleIdList><ArticleId IdType="pubmed">30602725</ArticleId></ArticleIdList></Reference><Reference><Citation>Tsunemi T et al. (2019) Increased lysosomal exocytosis induced by lysosomal Ca2+ channel agonists protects human dopaminergic neurons from &#x3b1;-Synuclein toxicity. J. Neurosci 39, 5760&#x2013;5772</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6636071</ArticleId><ArticleId IdType="pubmed">31097622</ArticleId></ArticleIdList></Reference><Reference><Citation>Campagno KE and Mitchell CH (2021) The P2X7 receptor in microglial cells modulates the endolysosomal axis, autophagy, and phagocytosis. Front. Cell. Neurosci 15, 645244.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8005553</ArticleId><ArticleId IdType="pubmed">33790743</ArticleId></ArticleIdList></Reference><Reference><Citation>Parenti G et al. (2021) The rapidly evolving view of lysosomal storage diseases. EMBO Mol. Med 13, 1&#x2013;21</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7863408</ArticleId><ArticleId IdType="pubmed">33459519</ArticleId></ArticleIdList></Reference><Reference><Citation>Wallings RL et al. (2019) Lysosomal dysfunction at the centre of Parkinson&#x2019;s disease and frontotemporal dementia/amyotrophic lateral sclerosis. Trends Neurosci. 42, 899&#x2013;912</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6931156</ArticleId><ArticleId IdType="pubmed">31704179</ArticleId></ArticleIdList></Reference><Reference><Citation>Alcalay RN et al. (2019) SMPD1 mutations, activity, and &#x3b1;-synuclein accumulation in Parkinson&#x2019;s disease. Mov. Disord 34, 526&#x2013;535</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6469643</ArticleId><ArticleId IdType="pubmed">30788890</ArticleId></ArticleIdList></Reference><Reference><Citation>Krohn L et al. (2020) Genetic, structural, and functional evidence link TMEM175 to synucleinopathies. Ann. Neurol 87, 139&#x2013;153</Citation><ArticleIdList><ArticleId IdType="pubmed">31658403</ArticleId></ArticleIdList></Reference><Reference><Citation>van Veen S et al. (2020) ATP13A2 deficiency disrupts lysosomal polyamine export. Nature 578, 419&#x2013;424</Citation><ArticleIdList><ArticleId IdType="pubmed">31996848</ArticleId></ArticleIdList></Reference><Reference><Citation>Renton AE et al. (2011) A hexanucleotide repeat expansion in C9ORF72 is the cause of chromosome 9p21-linked ALS-FTD. Neuron 72, 257&#x2013;268</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3200438</ArticleId><ArticleId IdType="pubmed">21944779</ArticleId></ArticleIdList></Reference><Reference><Citation>Baker M et al. (2006) Mutations in progranulin cause tau-negative frontotemporal dementia linked to chromosome 17. Nature 442, 916&#x2013;919</Citation><ArticleIdList><ArticleId IdType="pubmed">16862116</ArticleId></ArticleIdList></Reference><Reference><Citation>Van Deerlin VM et al. (2010) Common variants at 7p21 are associated with frontotemporal lobar degeneration with TDP-43 inclusions. Nat. Genet 42, 234&#x2013;239</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2828525</ArticleId><ArticleId IdType="pubmed">20154673</ArticleId></ArticleIdList></Reference><Reference><Citation>Van Acker ZP et al. (2019) Endo-lysosomal dysregulations and late-onset Alzheimer&#x2019;s disease: impact of genetic risk factors. Mol. Neurodegener 14, 1&#x2013;20</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6547588</ArticleId><ArticleId IdType="pubmed">31159836</ArticleId></ArticleIdList></Reference><Reference><Citation>Bourdenx M et al. (2021) Chaperone-mediated autophagy prevents collapse of the neuronal metastable proteome. Cell 184, 2696&#x2013;2714.e25</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8152331</ArticleId><ArticleId IdType="pubmed">33891876</ArticleId></ArticleIdList></Reference><Reference><Citation>Feng Q et al. (2020) MAPT/Tau accumulation represses autophagy flux by disrupting IST1-regulated ESCRT-III complex formation: a vicious cycle in Alzheimer neurodegeneration. Autophagy 16, 641&#x2013;658</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7138218</ArticleId><ArticleId IdType="pubmed">31223056</ArticleId></ArticleIdList></Reference><Reference><Citation>Finkbeiner S (2020) The autophagy lysosomal pathway and neurodegeneration. Cold Spring Harb. Perspect. Biol 12, 1&#x2013;20</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6773515</ArticleId><ArticleId IdType="pubmed">30936119</ArticleId></ArticleIdList></Reference><Reference><Citation>Hung C et al. (2021) SORL1 deficiency in human excitatory neurons causes APP-dependent defects in the endolysosome-autophagy network. Cell Rep. 35, 109259.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8220253</ArticleId><ArticleId IdType="pubmed">34133918</ArticleId></ArticleIdList></Reference><Reference><Citation>Lee JH et al. (2015) Presenilin 1 maintains lysosomal Ca2+ homeostasis via TRPML1 by regulating vATPase-mediated lysosome acidification. Cell Rep. 12, 1430&#x2013;1444</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4558203</ArticleId><ArticleId IdType="pubmed">26299959</ArticleId></ArticleIdList></Reference><Reference><Citation>Fedeli C et al. (2019) PSEN2 (presenilin 2) mutants linked to familial Alzheimer disease impair autophagy by altering Ca2+ homeostasis. Autophagy 15, 2044&#x2013;2062</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6844518</ArticleId><ArticleId IdType="pubmed">30892128</ArticleId></ArticleIdList></Reference><Reference><Citation>Ulland TK et al. (2017) TREM2 maintains microglial metabolic fitness in Alzheimer&#x2019;s disease. Cell 170, 649&#x2013;663.e13</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5573224</ArticleId><ArticleId IdType="pubmed">28802038</ArticleId></ArticleIdList></Reference><Reference><Citation>Xu H et al. (2021) In vitro amplification of pathogenic tau conserves disease-specific bioactive characteristics. Acta Neuropathol. 141, 193&#x2013;215</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7847465</ArticleId><ArticleId IdType="pubmed">33385254</ArticleId></ArticleIdList></Reference><Reference><Citation>Choi I et al. (2020) Microglia clear neuron-released &#x3b1;-synuclein via selective autophagy and prevent neurodegeneration. Nat. Commun 11, 1386.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7069981</ArticleId><ArticleId IdType="pubmed">32170061</ArticleId></ArticleIdList></Reference><Reference><Citation>Domert J et al. (2014) Spreading of amyloid-&#x3b2; peptides via neuritic cell-to-cell transfer is dependent on insufficient cellular clearance. Neurobiol. Dis 65, 82&#x2013;92</Citation><ArticleIdList><ArticleId IdType="pubmed">24412310</ArticleId></ArticleIdList></Reference><Reference><Citation>Cho MH et al. (2014) Autophagy in microglia degrades extracellular &#x3b2;-amyloid fibrils and regulates the NLRP3 inflammasome. Autophagy 10, 1761&#x2013;1775</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4198361</ArticleId><ArticleId IdType="pubmed">25126727</ArticleId></ArticleIdList></Reference><Reference><Citation>Minakaki G et al. (2018) Autophagy inhibition promotes SNCA/alpha-synuclein release and transfer via extracellular vesicles with a hybrid autophagosome-exosome-like phenotype. Autophagy 14, 98&#x2013;119</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5846507</ArticleId><ArticleId IdType="pubmed">29198173</ArticleId></ArticleIdList></Reference><Reference><Citation>He Y et al. (2011) Identification of a lysosomal pathway that modulates glucocorticoid signaling and the inflammatory response. Sci. Signal 4, ra44.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3684214</ArticleId><ArticleId IdType="pubmed">21730326</ArticleId></ArticleIdList></Reference><Reference><Citation>Ge W et al. (2015) The Roles of Lysosomes in inflammation and autoimmune diseases. Int. Rev. Immunol 34, 415&#x2013;431</Citation><ArticleIdList><ArticleId IdType="pubmed">25075736</ArticleId></ArticleIdList></Reference><Reference><Citation>Amick J et al. (2016) C9orf72 binds SMCR8, localizes to lysosomes, and regulates mTORC1 signaling. Mol. Biol. Cell 72, 3040&#x2013;3051</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5063613</ArticleId><ArticleId IdType="pubmed">27559131</ArticleId></ArticleIdList></Reference><Reference><Citation>O&#x2019;Rourke JG et al. (2016) C9orf72 is required for proper macrophage and microglial function in mice. Science 351, 1324&#x2013;1329</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5120541</ArticleId><ArticleId IdType="pubmed">26989253</ArticleId></ArticleIdList></Reference><Reference><Citation>Mccauley ME and Baloh RH (2019) Inflammation in ALS/FTD pathogenesis. Acta Neuropathol. 137, 715&#x2013;730</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6482122</ArticleId><ArticleId IdType="pubmed">30465257</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang M et al. (2020) C9orf72 associates with inactive Rag GTPases and regulates mTORC1-mediated autophagosomal and lysosomal biogenesis. Aging Cell 19, 1&#x2013;14</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7189992</ArticleId><ArticleId IdType="pubmed">32100453</ArticleId></ArticleIdList></Reference><Reference><Citation>Root J et al. (2021) Lysosome dysfunction as a cause of neurodegenerative diseases: Lessons from frontotemporal dementia and amyotrophic lateral sclerosis. Neurobiol. Dis 154, 105360.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8113138</ArticleId><ArticleId IdType="pubmed">33812000</ArticleId></ArticleIdList></Reference><Reference><Citation>DeJesus-Hernandez M et al. (2011) Expanded GGGGCC hexanucleotide repeat in noncoding region of C9ORF72 causes chromosome 9p-linked FTD and ALS. Neuron 72, 245&#x2013;256</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3202986</ArticleId><ArticleId IdType="pubmed">21944778</ArticleId></ArticleIdList></Reference><Reference><Citation>Tanaka Y et al. (2013) Increased lysosomal biogenesis in activated microglia and exacerbated neuronal damage after traumatic brain injury in progranulin-deficient mice. Neuroscience 250, 8&#x2013;19</Citation><ArticleIdList><ArticleId IdType="pubmed">23830905</ArticleId></ArticleIdList></Reference><Reference><Citation>Boss&#xf9; P et al. (2011) Loss of function mutations in the progranulin gene are related to pro-inflammatory cytokine dysregulation in frontotemporal lobar degeneration patients. J. Neuroinflammation 8,</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3141503</ArticleId><ArticleId IdType="pubmed">21645364</ArticleId></ArticleIdList></Reference><Reference><Citation>Galimberti D et al. (2015) Inflammatory molecules in frontotemporal dementia: cerebrospinal fluid signature of progranulin mutation carriers. Brain. Behav. Immun 49, 182&#x2013;187</Citation><ArticleIdList><ArticleId IdType="pubmed">26021560</ArticleId></ArticleIdList></Reference><Reference><Citation>Martens LH et al. (2012) Progranulin deficiency promotes neuroinflammation and neuron loss following toxin-induced injury. J. Clin. Invest 122, 3955&#x2013;3959</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3484443</ArticleId><ArticleId IdType="pubmed">23041626</ArticleId></ArticleIdList></Reference><Reference><Citation>Ward ME et al. (2017) Individuals with progranulin haploinsufficiency exhibit features of neuronal ceroid lipofuscinosis. Sci. Transl. Med 9, 1&#x2013;23</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5526610</ArticleId><ArticleId IdType="pubmed">28404863</ArticleId></ArticleIdList></Reference><Reference><Citation>Bonam SR et al. (2019) Lysosomes as a therapeutic target. Nat. Rev. Drug Discov 18, 923&#x2013;948</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7097195</ArticleId><ArticleId IdType="pubmed">31477883</ArticleId></ArticleIdList></Reference><Reference><Citation>Kiernan MC et al. (2021) Improving clinical trial outcomes in amyotrophic lateral sclerosis. Nat. Rev. Neurol 17, 104&#x2013;118</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7747476</ArticleId><ArticleId IdType="pubmed">33340024</ArticleId></ArticleIdList></Reference><Reference><Citation>Lodato MA et al. (2018) Aging and neurodegeneration are associated with increased mutations in single human neurons. Science 559, 555&#x2013;559</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5831169</ArticleId><ArticleId IdType="pubmed">29217584</ArticleId></ArticleIdList></Reference><Reference><Citation>Grubman A et al. (2019) A single-cell atlas of entorhinal cortex from individuals with Alzheimer&#x2019;s disease reveals cell-type-specific gene expression regulation. Nat. Neurosci 22, 2087&#x2013;2097</Citation><ArticleIdList><ArticleId IdType="pubmed">31768052</ArticleId></ArticleIdList></Reference><Reference><Citation>Hook PW et al. (2018) Single-cell RNA-Seq of mouse dopaminergic neurons informs candidate gene selection for sporadic Parkinson disease. Am. J. Hum. Genet 102, 427&#x2013;446</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5985341</ArticleId><ArticleId IdType="pubmed">29499164</ArticleId></ArticleIdList></Reference><Reference><Citation>Hoffman JM et al. (2017) Proteomics and metabolomics in ageing research: from biomarkers to systems biology. Essays Biochem. 61, 379&#x2013;388</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5743054</ArticleId><ArticleId IdType="pubmed">28698311</ArticleId></ArticleIdList></Reference><Reference><Citation>Goker-Alpan O et al. (2006) Glucocerebrosidase mutations are an important risk factor for Lewy body disorders. Neurology 67,</Citation><ArticleIdList><ArticleId IdType="pubmed">16790605</ArticleId></ArticleIdList></Reference><Reference><Citation>Gan-Or Z et al. (2015) GBA mutations are associated with rapid eye movement sleep behavior disorder. Ann. Clin. Transl. Neurol 2, 941&#x2013;945</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4574811</ArticleId><ArticleId IdType="pubmed">26401515</ArticleId></ArticleIdList></Reference><Reference><Citation>Blanz J and Saftig P (2016) Parkinson&#x2019;s disease: acid-glucocerebrosidase activity and alpha-synuclein clearance. J. Neurochem 139, 198&#x2013;215</Citation><ArticleIdList><ArticleId IdType="pubmed">26860955</ArticleId></ArticleIdList></Reference><Reference><Citation>Aflaki E et al. (2017) The complicated relationship between Gaucher disease and parkinsonism: insights from a rare disease. Neuron 93, 737&#x2013;746</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5327952</ArticleId><ArticleId IdType="pubmed">28231462</ArticleId></ArticleIdList></Reference><Reference><Citation>Do J et al. (2019) Glucocerebrosidase and its relevance to Parkinson disease. Mol. Neurodegener 14, 1&#x2013;16</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6716912</ArticleId><ArticleId IdType="pubmed">31464647</ArticleId></ArticleIdList></Reference><Reference><Citation>Aflaki E et al. (2016) A new glucocerebrosidase chaperone reduces &#x3b1;-synuclein and glycolipid levels in iPSC-derived dopaminergic neurons from patients with Gaucher disease and parkinsonism. J. Neurosci 36, 7441&#x2013;7452</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4945664</ArticleId><ArticleId IdType="pubmed">27413154</ArticleId></ArticleIdList></Reference><Reference><Citation>Sch&#xf6;ndorf DC et al. (2014) IPSC-derived neurons from GBA1-associated Parkinson&#x2019;s disease patients show autophagic defects and impaired calcium homeostasis. Nat. Commun 5, 4028.</Citation><ArticleIdList><ArticleId IdType="pubmed">24905578</ArticleId></ArticleIdList></Reference><Reference><Citation>Gegg ME et al. (2015) No evidence for substrate accumulation in Parkinson brains with GBA mutations. Mov. Disord 30, 1085&#x2013;1089</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4529481</ArticleId><ArticleId IdType="pubmed">26096906</ArticleId></ArticleIdList></Reference><Reference><Citation>G&#xfc;ndner AL et al. (2019) Path mediation analysis reveals GBA impacts Lewy body disease status by increasing &#x3b1;-synuclein levels. Neurobiol. Dis 121, 205&#x2013;213</Citation><ArticleIdList><ArticleId IdType="pubmed">30236861</ArticleId></ArticleIdList></Reference><Reference><Citation>Mazzulli JR et al. (2011) Gaucher disease glucocerebrosidase and &#x3b1;-synuclein form a bidirectional pathogenic loop in synucleinopathies. Cell 146, 37&#x2013;52</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3132082</ArticleId><ArticleId IdType="pubmed">21700325</ArticleId></ArticleIdList></Reference><Reference><Citation>Mazzulli JR et al. (2016) Activation of &#x3b2;-glucocerebrosidase reduces pathological &#x3b1;-synuclein and restores lysosomal function in Parkinson&#x2019;s patient midbrain neurons. J. Neurosci 36, 7693&#x2013;7706</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4951575</ArticleId><ArticleId IdType="pubmed">27445146</ArticleId></ArticleIdList></Reference><Reference><Citation>Klumperman J and Raposo G (2014) The complex ultrastructure of the endolysosomal system. Cold Spring Harb. Perspect. Biol 6, a016857.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4176003</ArticleId><ArticleId IdType="pubmed">24851870</ArticleId></ArticleIdList></Reference><Reference><Citation>Abu-Remaileh M et al. (2017) Lysosomal metabolomics reveals V-ATPase- and mTOR-dependent regulation of amino acid efflux from lysosomes. Science 358, 807&#x2013;813</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5704967</ArticleId><ArticleId IdType="pubmed">29074583</ArticleId></ArticleIdList></Reference><Reference><Citation>Wyant GA et al. (2017) mTORC1 activator SLC38A9 is required to efflux essential amino acids from lysosomes and use protein as a nutrient. Cell 171, 642&#x2013;647.e12</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5704964</ArticleId><ArticleId IdType="pubmed">29053970</ArticleId></ArticleIdList></Reference><Reference><Citation>Davis OB et al. (2021) NPC1-mTORC1 signaling couples cholesterol sensing to organelle homeostasis and is a targetable pathway in Niemann-Pick Type C. Dev. Cell 56, 260&#x2013;276.e7</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8919971</ArticleId><ArticleId IdType="pubmed">33308480</ArticleId></ArticleIdList></Reference><Reference><Citation>Singh J et al. (2020) Systematic comparison of strategies for the enrichment of lysosomes by data independent acquisition. J. Proteome Res 19, 371&#x2013;381</Citation><ArticleIdList><ArticleId IdType="pubmed">31738065</ArticleId></ArticleIdList></Reference><Reference><Citation>Wyant GA et al. (2018) NUFIP1 is a ribosome receptor for starvation-induced ribophagy. Science 360, 751&#x2013;758</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6020066</ArticleId><ArticleId IdType="pubmed">29700228</ArticleId></ArticleIdList></Reference><Reference><Citation>Logan T et al. (2021) Rescue of a lysosomal storage disorder caused by Grn loss of function with a brain penetrant progranulin biologic. Cell 184, 4651&#x2013;4668.e25</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8489356</ArticleId><ArticleId IdType="pubmed">34450028</ArticleId></ArticleIdList></Reference><Reference><Citation>Evers BM et al. (2017) Lipidomic and transcriptomic basis of lysosomal dysfunction in progranulin deficiency. Cell Rep. 20, 2565&#x2013;2574</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5757843</ArticleId><ArticleId IdType="pubmed">28903038</ArticleId></ArticleIdList></Reference><Reference><Citation>Holler CJ et al. (2017) Intracellular proteolysis of progranulin generates stable, lysosomal granulins that are haploinsufficient in patients with frontotemporal dementia caused by GRN mutations. eNeuro 4,</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5562298</ArticleId><ArticleId IdType="pubmed">28828399</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhou X et al. (2017) The interaction between progranulin and prosaposin is mediated by granulins and the linker region between saposin B and C. J. Neurochem 143, 236&#x2013;243</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5630500</ArticleId><ArticleId IdType="pubmed">28640985</ArticleId></ArticleIdList></Reference><Reference><Citation>Dong XP et al. (2008) The type IV mucolipidosis-associated protein TRPML1 is an endolysosomal iron release channel. Nature 455, 992&#x2013;996</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4301259</ArticleId><ArticleId IdType="pubmed">18794901</ArticleId></ArticleIdList></Reference><Reference><Citation>Cang C et al. (2013) mTOR regulates lysosomal ATP-sensitive two-pore Na+ channels to adapt to metabolic state. Cell 152, 778&#x2013;790</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3908667</ArticleId><ArticleId IdType="pubmed">23394946</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang W et al. (2015) Up-regulation of lysosomal TRPML1 channels is essential for lysosomal adaptation to nutrient starvation. Proc. Natl. Acad. Sci. U. S. A 112, E1373&#x2013;E1381</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4371935</ArticleId><ArticleId IdType="pubmed">25733853</ArticleId></ArticleIdList></Reference><Reference><Citation>Li G et al. (2019) Control of lysosomal TRPML1 channel activity and exosome release by acid ceramidase in mouse podocytes. Am. J. Physiol. - Cell Physiol 317, C481&#x2013;C494</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6766620</ArticleId><ArticleId IdType="pubmed">31268777</ArticleId></ArticleIdList></Reference><Reference><Citation>Chin MY et al. (2021) Genetically encoded, pH-sensitive mTFP1 biosensor for probing lysosomal pH. ACS Sensors 6, 2168&#x2013;2180</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8240087</ArticleId><ArticleId IdType="pubmed">34102054</ArticleId></ArticleIdList></Reference><Reference><Citation>Jinn S et al. (2019) Functionalization of the TMEM175 p.M393T variant as a risk factor for Parkinson disease. Hum. Mol. Genet 28, 3244&#x2013;3254</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6859430</ArticleId><ArticleId IdType="pubmed">31261387</ArticleId></ArticleIdList></Reference><Reference><Citation>Chia R et al. (2021) Genome sequencing analysis identifies new loci associated with Lewy body dementia and provides insights into its genetic architecture. Nat. Genet 53, 294&#x2013;303</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7946812</ArticleId><ArticleId IdType="pubmed">33589841</ArticleId></ArticleIdList></Reference><Reference><Citation>Cang C et al. (2015) TMEM175 is an organelle K+ channel regulating lysosomal function. Cell 162, 1101&#x2013;1112</Citation><ArticleIdList><ArticleId IdType="pubmed">26317472</ArticleId></ArticleIdList></Reference><Reference><Citation>Wie J et al. (2021) A growth-factor-activated lysosomal K+ channel regulates Parkinson&#x2019;s pathology. Nature 591, 431&#x2013;437</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7979525</ArticleId><ArticleId IdType="pubmed">33505021</ArticleId></ArticleIdList></Reference><Reference><Citation>Jinn S et al. (2017) TMEM175 deficiency impairs lysosomal and mitochondrial function and increases &#x3b1;-synuclein aggregation. Proc. Natl. Acad. Sci. U. S. A 114, 2389&#x2013;2394</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5338534</ArticleId><ArticleId IdType="pubmed">28193887</ArticleId></ArticleIdList></Reference><Reference><Citation>Freeman D et al. (2013) Alpha-synuclein induces lysosomal rupture and cathepsin dependent reactive oxygen species following endocytosis. PLoS One 8, e62143.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3636263</ArticleId><ArticleId IdType="pubmed">23634225</ArticleId></ArticleIdList></Reference><Reference><Citation>Jiang P et al. (2017) Impaired endo-lysosomal membrane integrity accelerates the seeding progression of &#x3b1;-synuclein aggregates. Sci. Rep 7, 7690.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5550496</ArticleId><ArticleId IdType="pubmed">28794446</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen JJ et al. (2019) Compromised function of the ESCRT pathway promotes endolysosomal escape of tau seeds and propagation of tau aggregation. J. Biol. Chem 294, 18952&#x2013;18966</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6916486</ArticleId><ArticleId IdType="pubmed">31578281</ArticleId></ArticleIdList></Reference><Reference><Citation>See SK et al. (2021) PIKfyve inhibition blocks endolysosomal escape of &#x3b1;-synuclein fibrils and spread of &#x3b1;-synuclein aggregation. Bioarxiv DOI: 10.1101/2021.01.21.427704</Citation><ArticleIdList><ArticleId IdType="doi">10.1101/2021.01.21.427704</ArticleId></ArticleIdList></Reference><Reference><Citation>Polanco JC et al. (2021) Exosomes induce endolysosomal permeabilization as a gateway by which exosomal tau seeds escape into the cytosol. Acta Neuropathol. 141, 235&#x2013;256</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7847444</ArticleId><ArticleId IdType="pubmed">33417012</ArticleId></ArticleIdList></Reference><Reference><Citation>Okada M et al. (2014) The lysosome rupture-activated TAK1-JNK pathway regulates NLRP3 inflammasome activation. J. Biol. Chem 289, 32926&#x2013;32936</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4239639</ArticleId><ArticleId IdType="pubmed">25288801</ArticleId></ArticleIdList></Reference><Reference><Citation>Manna S et al. (2018) Immunomodulation of the NLRP3 inflammasome through structure-based activator design and functional regulation via lysosomal rupture. ACS Cent. Sci 4, 985&#x2013;995</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6107863</ArticleId><ArticleId IdType="pubmed">30159395</ArticleId></ArticleIdList></Reference><Reference><Citation>Bonet-Ponce L et al. (2020) LRRK2 mediates tubulation and vesicle sorting from lysosomes. Sci. Adv 6, eabb2454.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7673727</ArticleId><ArticleId IdType="pubmed">33177079</ArticleId></ArticleIdList></Reference><Reference><Citation>Wong YC et al. (2018) Mitochondria-lysosome contacts regulate mitochondrial fission via Rab7 GTP hydrolysis. Nature 554, 382&#x2013;386</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6209448</ArticleId><ArticleId IdType="pubmed">29364868</ArticleId></ArticleIdList></Reference><Reference><Citation>Kim S et al. (2021) Dysregulation of mitochondria-lysosome contacts by GBA1 dysfunction in dopaminergic neuronal models of Parkinson&#x2019;s disease. Nat. Commun 12, 1807.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7985376</ArticleId><ArticleId IdType="pubmed">33753743</ArticleId></ArticleIdList></Reference><Reference><Citation>Obermeier B et al. (2016) The blood &#x2013; brain barrier. Handb. Clin. Neurol 133, 39&#x2013;59</Citation><ArticleIdList><ArticleId IdType="pubmed">27112670</ArticleId></ArticleIdList></Reference><Reference><Citation>Colonna M and Butovsky O (2017) Microglia function in the central nervous system during health and neurodegeneration. Annu. Rev. Physiol 35, 441&#x2013;468</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8167938</ArticleId><ArticleId IdType="pubmed">28226226</ArticleId></ArticleIdList></Reference><Reference><Citation>Verkhratsky A (2020) Untangling complexities of glial-neuronal communications&#x202f;: astroglial metabolic cascades orchestrate tonic inhibition in the thalamus. Neuron 108, 585&#x2013;587</Citation><ArticleIdList><ArticleId IdType="pubmed">33242426</ArticleId></ArticleIdList></Reference><Reference><Citation>Aflaki E et al. (2020) A characterization of Gaucher iPS-derived astrocytes: potential implications for Parkinson disease. Neurobiol. Dis 134, 10464</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6980699</ArticleId><ArticleId IdType="pubmed">31669751</ArticleId></ArticleIdList></Reference><Reference><Citation>Pressey SNR et al. (2012) Early glial activation, synaptic changes and axonal pathology in the thalamocortical system of Niemann-Pick type C1 mice. Neurobiol. Dis 45, 1086&#x2013;1100</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3657200</ArticleId><ArticleId IdType="pubmed">22198570</ArticleId></ArticleIdList></Reference><Reference><Citation>Colombo A et al. (2021) Loss of NPC1 enhances phagocytic uptake and impairs lipid trafficking in microglia. Nat. Commun 12, 1158.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7904859</ArticleId><ArticleId IdType="pubmed">33627648</ArticleId></ArticleIdList></Reference><Reference><Citation>Gonugunta VK et al. (2017) Trafficking-mediated STING degradation requires sorting to acidified endolysosomes and can be targeted to enhance anti-tumor response. Cell Rep. 21, 3234&#x2013;3242</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5905341</ArticleId><ArticleId IdType="pubmed">29241549</ArticleId></ArticleIdList></Reference><Reference><Citation>Chu TT et al. (2021) Tonic prime-boost of STING signalling mediates Niemann&#x2013;Pick disease type C. Nature DOI: 10.1038/s41586-021-03762-2</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41586-021-03762-2</ArticleId><ArticleId IdType="pmc">PMC8859990</ArticleId><ArticleId IdType="pubmed">34290407</ArticleId></ArticleIdList></Reference><Reference><Citation>Aoki Y et al. (2017) C9orf72 and RAB7L1 regulate vesicle trafficking in amyotrophic lateral sclerosis and frontotemporal dementia. Brain 140, 887&#x2013;897</Citation><ArticleIdList><ArticleId IdType="pubmed">28334866</ArticleId></ArticleIdList></Reference><Reference><Citation>Shi Y et al. (2018) Haploinsufficiency leads to neurodegeneration in C9ORF72 ALS/FTD human induced motor neurons. Nat. Med 24, 313&#x2013;325</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6112156</ArticleId><ArticleId IdType="pubmed">29400714</ArticleId></ArticleIdList></Reference><Reference><Citation>Corrionero A and Horvitz HR (2018) A C9orf72 ALS/FTD ortholog acts in endolysosomal degradation and lysosomal homeostasis. Curr. Biol 28, 1522&#x2013;1535.e5</Citation><ArticleIdList><ArticleId IdType="pubmed">29731301</ArticleId></ArticleIdList></Reference><Reference><Citation>Burberry A et al. (2016) Loss-of-function mutations in the C9ORF72 mouse ortholog cause fatal autoimmune disease. Sci. Transl. Med 8, 347ra93</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5024536</ArticleId><ArticleId IdType="pubmed">27412785</ArticleId></ArticleIdList></Reference><Reference><Citation>Mori K et al. (2013) The C9orf72 GGGGCC repeat is translated into aggregating dipeptide-repeat proteins in FTLD/ALS. Science 339, 1335&#x2013;1339</Citation><ArticleIdList><ArticleId IdType="pubmed">23393093</ArticleId></ArticleIdList></Reference><Reference><Citation>Ash PEA et al. (2013) Unconventional translation of C9ORF72 GGGGCC expansion generates insoluble polypeptides specific to c9FTD/ALS. Neuron 77, 639&#x2013;646</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3593233</ArticleId><ArticleId IdType="pubmed">23415312</ArticleId></ArticleIdList></Reference><Reference><Citation>Donnelly CJ et al. (2013) RNA toxicity from the ALS/FTD C9ORF72 expansion is mitigated by antisense intervention. Neuron 80, 415&#x2013;428</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4098943</ArticleId><ArticleId IdType="pubmed">24139042</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhu Q et al. (2020) Reduced C9ORF72 function exacerbates gain of toxicity from ALS/FTD-causing repeat expansion in C9orf72. Nat. Neurosci 23, 615&#x2013;624</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7384305</ArticleId><ArticleId IdType="pubmed">32284607</ArticleId></ArticleIdList></Reference><Reference><Citation>McCauley ME et al. (2020) C9orf72 in myeloid cells suppresses STING-induced inflammation. Nature 585, 96&#x2013;101</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7484469</ArticleId><ArticleId IdType="pubmed">32814898</ArticleId></ArticleIdList></Reference><Reference><Citation>Lall D et al. (2021) C9orf72 deficiency promotes microglial-mediated synaptic loss in aging and amyloid accumulation. Neuron 109, 2275&#x2013;2291.e8</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8298293</ArticleId><ArticleId IdType="pubmed">34133945</ArticleId></ArticleIdList></Reference><Reference><Citation>Streubel-Gallasch L et al. (2021) Parkinson&#x2019;s disease&#x2013;associated LRRK2 interferes with astrocyte-mediated alpha-synuclein clearance. Mol. Neurobiol DOI: 10.1007/s12035-021-02327-8</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s12035-021-02327-8</ArticleId><ArticleId IdType="pmc">PMC8257537</ArticleId><ArticleId IdType="pubmed">33629273</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang J et al. (2020) Neurotoxic microglia promote TDP-43 proteinopathy in progranulin deficiency. Nature 588, 459&#x2013;465</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7746606</ArticleId><ArticleId IdType="pubmed">32866962</ArticleId></ArticleIdList></Reference><Reference><Citation>LaFerla FM and Green KN (2012) Animal models of Alzheimer disease. Cold Spring Harb. Perspect. Med 2, a006320.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3543097</ArticleId><ArticleId IdType="pubmed">23002015</ArticleId></ArticleIdList></Reference><Reference><Citation>Volta M and Melrose H (2017) LRRK2 mouse models&#x202f;: dissecting the behavior, striatal neurochemistry and neurophysiology of PD pathogenesis. Biochem. Soc. Trans 45, 113&#x2013;122</Citation><ArticleIdList><ArticleId IdType="pubmed">28202664</ArticleId></ArticleIdList></Reference><Reference><Citation>Dawson TM et al. (2018) Animal models of neurodegenerative diseases. Nat. Neurosci 21, 1370&#x2013;1379</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6615039</ArticleId><ArticleId IdType="pubmed">30250265</ArticleId></ArticleIdList></Reference><Reference><Citation>Fernandes HJR et al. (2016) ER stress and autophagic perturbations lead to elevated extracellular a-synuclein in GBA-N370S Parkinson&#x2019;s iPSC-derived dopamine neurons. Stem Cell Reports 6, 342&#x2013;356</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4788783</ArticleId><ArticleId IdType="pubmed">26905200</ArticleId></ArticleIdList></Reference><Reference><Citation>Burbulla LF et al. (2017) Dopamine oxidation mediates mitochondrial and lysosomal dysfunction in Parkinson&#x2019; s disease. Science 357, 1255&#x2013;1261</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6021018</ArticleId><ArticleId IdType="pubmed">28882997</ArticleId></ArticleIdList></Reference><Reference><Citation>Verheyen A et al. (2018) Genetically engineered iPSC-derived FTDP-17 MAPT neurons display mutation-specific neurodegenerative and neurodevelopmental phenotypes. Stem Cell Reports 11, 363&#x2013;379</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6093179</ArticleId><ArticleId IdType="pubmed">30057263</ArticleId></ArticleIdList></Reference><Reference><Citation>di Domenico A et al. (2019) Patient-specific iPSC-derived astrocytes contribute to non-cell-autonomous neurodegeneration in Parkinson&#x2019;s disease. Stem Cell Reports 12, 213&#x2013;229</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6372974</ArticleId><ArticleId IdType="pubmed">30639209</ArticleId></ArticleIdList></Reference><Reference><Citation>Lang C et al. (2019) Single-cell sequencing of iPSC-dopamine neurons reconstructs disease progression and identifies HDAC4 as a regulator of Parkinson cell phenotypes. Cell Stem Cell 24, 93&#x2013;106.e6</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6327112</ArticleId><ArticleId IdType="pubmed">30503143</ArticleId></ArticleIdList></Reference><Reference><Citation>Okarmus J et al. (2020) Lysosomal perturbations in human dopaminergic neurons derived from induced pluripotent stem cells with PARK2 mutation. Sci. Rep 10, 1&#x2013;16</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7314796</ArticleId><ArticleId IdType="pubmed">32581291</ArticleId></ArticleIdList></Reference><Reference><Citation>Gowrishankar S et al. (2021) Overlapping roles of JIP3 and JIP4 in promoting axonal transport of lysosomes in human iPSC-derived neurons. Mol Biol Cell. 32, 1094&#x2013;1103</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8351540</ArticleId><ArticleId IdType="pubmed">33788575</ArticleId></ArticleIdList></Reference><Reference><Citation>Haenseler W et al. (2017) Excess &#x3b1;-synuclein compromises phagocytosis in iPSC-derived macrophages. Sci. Rep 7,</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5567139</ArticleId><ArticleId IdType="pubmed">28827786</ArticleId></ArticleIdList></Reference><Reference><Citation>Garcia-Reitboeck P et al. (2018) Human induced pluripotent stem cell-derived microglia-ike cells harboring TREM2 missense mutations show specific deficits in phagocytosis. Cell Rep. 24, 2300&#x2013;2311</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6130048</ArticleId><ArticleId IdType="pubmed">30157425</ArticleId></ArticleIdList></Reference><Reference><Citation>Raja WK et al. (2016) Self-organizing 3D human neural tissue derived from induced pluripotent stem cells recapitulate Alzheimer&#x2019;s disease phenotypes. PLoS One 11, 1&#x2013;18</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5021368</ArticleId><ArticleId IdType="pubmed">27622770</ArticleId></ArticleIdList></Reference><Reference><Citation>Smits LM et al. (2019) Modeling Parkinson&#x2019;s disease in midbrain-like organoids. npj Parkinson&#x2019;s Disease 5, 5</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6450999</ArticleId><ArticleId IdType="pubmed">30963107</ArticleId></ArticleIdList></Reference><Reference><Citation>Kim H et al. (2019) Modeling G2019S-LRRK2 sporadic parkinson&#x2019;s disease in 3D midbrain organoids. Stem Cell Reports 12, 518&#x2013;531</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6410341</ArticleId><ArticleId IdType="pubmed">30799274</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhao J et al. (2020) APOE4 exacerbates synapse loss and neurodegeneration in Alzheimer&#x2019;s disease patient iPSC-derived cerebral organoids. Nat. Commun 11, 5540.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7608683</ArticleId><ArticleId IdType="pubmed">33139712</ArticleId></ArticleIdList></Reference><Reference><Citation>Wulansari N et al. (2021) Neurodevelopmental defects and neurodegenerative phenotypes in human brain organoids carrying Parkinson&#x2019;s disease-linked DNAJC6 mutations. Sci. Adv 7, 1&#x2013;18</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7888924</ArticleId><ArticleId IdType="pubmed">33597231</ArticleId></ArticleIdList></Reference><Reference><Citation>Do C et al. (2017) Genetic-epigenetic interactions in cis: A major focus in the post-GWAS era. Genome Biol. 18, 1&#x2013;22</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5477265</ArticleId><ArticleId IdType="pubmed">28629478</ArticleId></ArticleIdList></Reference><Reference><Citation>Alcal&#xe0;-Vida R et al. (2021) Epigenetic mechanisms underlying enhancer modulation of neuronal identity, neuronal activity and neurodegeneration. Neurobiol. Dis 147, 105155.</Citation><ArticleIdList><ArticleId IdType="pubmed">33127472</ArticleId></ArticleIdList></Reference><Reference><Citation>Hassan S et al. (2017) The role of epigenetics in lysosomal storage disorders: uncharted territory. Mol. Genet. Metab 122, 10&#x2013;18</Citation><ArticleIdList><ArticleId IdType="pubmed">28918065</ArticleId></ArticleIdList></Reference><Reference><Citation>Platt FM et al. (2018) Lysosomal storage diseases. Nat. Rev. Disease Primers 4, 27.</Citation><ArticleIdList><ArticleId IdType="pubmed">30275469</ArticleId></ArticleIdList></Reference><Reference><Citation>van Heesbeen HJ and Smidt MP (2019) Entanglement of genetics and epigenetics in Parkinson&#x2019;s disease. Front. Neurosci 13, 277.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6449477</ArticleId><ArticleId IdType="pubmed">30983962</ArticleId></ArticleIdList></Reference><Reference><Citation>Jain N and Chen-Plotkin AS (2018) Genetic modifiers in neurodegeneration. Curr. Genet. Med. Rep 6, 11&#x2013;19</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6028053</ArticleId><ArticleId IdType="pubmed">29977663</ArticleId></ArticleIdList></Reference><Reference><Citation>Gilbert LA et al. (2014) Resource genome-scale CRISPR-mediated control of gene repression and activation. Cell 159, 647&#x2013;661</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4253859</ArticleId><ArticleId IdType="pubmed">25307932</ArticleId></ArticleIdList></Reference><Reference><Citation>Ferguson SM (2019) Neuronal lysosomes. Neurosci. Lett 697, 1&#x2013;9</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6170731</ArticleId><ArticleId IdType="pubmed">29626653</ArticleId></ArticleIdList></Reference><Reference><Citation>Kreher C et al. (2021) Lysosomal functions in glia associated with neurodegeneration. Biomolecules 11, 1&#x2013;17</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7999372</ArticleId><ArticleId IdType="pubmed">33803137</ArticleId></ArticleIdList></Reference><Reference><Citation>Gowrishankar S et al. (2017) Impaired JIP3-dependent axonal lysosome transport promotes amyloid plaque pathology. J. Cell Biol 216, 3291&#x2013;3305</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5626538</ArticleId><ArticleId IdType="pubmed">28784610</ArticleId></ArticleIdList></Reference><Reference><Citation>Far&#xed;as GG et al. (2017) BORC/kinesin-1 ensemble drives polarized transport of lysosomes into the axon. Proc. Natl. Acad. Sci. U. S. A 114, E2955&#x2013;E2964</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5389300</ArticleId><ArticleId IdType="pubmed">28320970</ArticleId></ArticleIdList></Reference><Reference><Citation>Farfel-Becker T et al. (2019) Neuronal soma-derived degradative lysosomes are continuously delivered to distal axons to maintain local degradation capacity. Cell Rep. 28, 51&#x2013;64.e4</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6696943</ArticleId><ArticleId IdType="pubmed">31269450</ArticleId></ArticleIdList></Reference><Reference><Citation>Roney JC et al. (2021) Lipid-mediated motor-adaptor sequestration impairs axonal lysosome delivery leading to autophagic stress and dystrophy in Niemann-Pick type C. Dev. Cell 56, 1452&#x2013;1468.e8</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8137671</ArticleId><ArticleId IdType="pubmed">33878344</ArticleId></ArticleIdList></Reference><Reference><Citation>Moreno-Garc&#xed;a A et al. (2018) An overview of the role of lipofuscin in age-related neurodegeneration. Front. Neurosci 12, 1&#x2013;13</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6041410</ArticleId><ArticleId IdType="pubmed">30026686</ArticleId></ArticleIdList></Reference><Reference><Citation>Geraets RD et al. (2016) Moving towards effective therapeutic strategies for Neuronal Ceroid Lipofuscinosis. Orphanet J. Rare Dis 11, 40.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4833901</ArticleId><ArticleId IdType="pubmed">27083890</ArticleId></ArticleIdList></Reference><Reference><Citation>Braak E et al. (2001) &#x3b1;-Synuclein immunopositive Parkinson&#x2019;s disease-related inclusion bodies in lower brain stem nuclei. Acta Neuropathol. 101, 195&#x2013;201</Citation><ArticleIdList><ArticleId IdType="pubmed">11307617</ArticleId></ArticleIdList></Reference><Reference><Citation>Lv Z et al. (2011) Increased iron levels correlate with the selective nigral dopaminergic neuron degeneration in Parkinson&#x2019;s disease. J. Neural Transm 118, 361&#x2013;369</Citation><ArticleIdList><ArticleId IdType="pubmed">20556443</ArticleId></ArticleIdList></Reference><Reference><Citation>Wellings TP et al. (2017) Altered neurofilament protein expression in the lateral vestibular nucleus in Parkinson&#x2019;s disease. Exp. Brain Res 235, 3695&#x2013;3708</Citation><ArticleIdList><ArticleId IdType="pubmed">28929183</ArticleId></ArticleIdList></Reference><Reference><Citation>Chai N et al. (2020) Genome-wide synthetic lethal CRISPR screen identifies FIS1 as a genetic interactor of ALS-linked C9ORF72. Brain Res. 1728, 146601.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7539795</ArticleId><ArticleId IdType="pubmed">31843624</ArticleId></ArticleIdList></Reference><Reference><Citation>Tian R et al. (2021) Genome-wide CRISPRi/a screens in human neurons link lysosomal failure to ferroptosis. Nat. Neurosci 24, 1020&#x2013;1034</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8254803</ArticleId><ArticleId IdType="pubmed">34031600</ArticleId></ArticleIdList></Reference><Reference><Citation>Diaz-font SA et al. (2005) A mutation within the saposin D domain in a Gaucher disease patient with normal glucocerebrosidase activity. Hum Genet DOI: 10.1007/s00439-005-1288-x</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00439-005-1288-x</ArticleId><ArticleId IdType="pubmed">15856305</ArticleId></ArticleIdList></Reference><Reference><Citation>Oji Y et al. (2020) Variants in saposin D domain of prosaposin gene linked to Parkinson &#x2019; s disease. Brain 143, 1190&#x2013;1205</Citation><ArticleIdList><ArticleId IdType="pubmed">32201884</ArticleId></ArticleIdList></Reference><Reference><Citation>Kanfer G et al. (2021) Image-based pooled whole-genome CRISPRi screening for subcellular phenotypes. J. Cell Biol 220, e202006180.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7816647</ArticleId><ArticleId IdType="pubmed">33464298</ArticleId></ArticleIdList></Reference><Reference><Citation>Ryan SD et al. (2013) Isogenic human iPSC Parkinson&#x2019;s model shows nitrosative stress-induced dysfunction in MEF2-PGC1&#x3b1; transcription. Cell 155, 1351&#x2013;1364</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4028128</ArticleId><ArticleId IdType="pubmed">24290359</ArticleId></ArticleIdList></Reference><Reference><Citation>Reinhardt P et al. (2013) Genetic correction of a LRRK2 mutation in human iPSCs links parkinsonian neurodegeneration to ERK-dependent changes in gene expression. Cell Stem Cell 12, 354&#x2013;367</Citation><ArticleIdList><ArticleId IdType="pubmed">23472874</ArticleId></ArticleIdList></Reference><Reference><Citation>Nickels SL et al. (2019) Impaired serine metabolism complements LRRK2-G2019S pathogenicity in PD patients. Park. Relat. Disord 67, 48&#x2013;55</Citation><ArticleIdList><ArticleId IdType="pubmed">31621607</ArticleId></ArticleIdList></Reference><Reference><Citation>Ysselstein D et al. (2019) LRRK2 kinase activity regulates lysosomal glucocerebrosidase in neurons derived from Parkinson&#x2019;s disease patients. Nat. Commun 10, 5570.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6895201</ArticleId><ArticleId IdType="pubmed">31804465</ArticleId></ArticleIdList></Reference><Reference><Citation>Sosero YL et al. (2021) LRRK2 p.M1646T is associated with glucocerebrosidase activity and with Parkinson&#x2019;s disease. Neurobiol. Aging 103, 142.e1&#x2013;142.e5</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8178224</ArticleId><ArticleId IdType="pubmed">33781610</ArticleId></ArticleIdList></Reference><Reference><Citation>Saxena S and Caroni P (2011) Selective neuronal vulnerability in neurodegenerative diseases: from stressor thresholds to degeneration. Neuron 71, 35&#x2013;48</Citation><ArticleIdList><ArticleId IdType="pubmed">21745636</ArticleId></ArticleIdList></Reference><Reference><Citation>Pandya VA and Patani R (2021) Region-specific vulnerability in neurodegeneration: lessons from normal ageing. Ageing Res. Rev 67, 101311.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8024744</ArticleId><ArticleId IdType="pubmed">33639280</ArticleId></ArticleIdList></Reference><Reference><Citation>Del-aguila JL et al. (2019) A single-nuclei RNA sequencing study of Mendelian and sporadic AD in the human brain. Alzheimer&#x2019;s Res. Ther 11, 71.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6689177</ArticleId><ArticleId IdType="pubmed">31399126</ArticleId></ArticleIdList></Reference><Reference><Citation>Mathys H et al. (2019) Single-cell transcriptomic analysis of Alzheimer&#x2019;s disease. Nat. Neurosci 570, 2087&#x2013;2097</Citation></Reference><Reference><Citation>Johnson ECB et al. (2020) Large-scale proteomic analysis of Alzheimer&#x2019;s disease brain and cerebrospinal fluid reveals early changes in energy metabolism associated with microglia and astrocyte activation. Nat. Med 26, 769&#x2013;780</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7405761</ArticleId><ArticleId IdType="pubmed">32284590</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhou Y et al. (2020) Human and mouse single-nucleus transcriptomics reveal TREM2-dependent and - independent cellular responses in Alzheimer&#x2019;s disease. Nat. Med 26, 131&#x2013;142</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6980793</ArticleId><ArticleId IdType="pubmed">31932797</ArticleId></ArticleIdList></Reference><Reference><Citation>Alcalay RN et al. (2020) Higher urine bis(monoacylglycerol)phosphate levels in LRRK2 G2019S mutation carriers: implications for therapeutic development. Mov. Disord 35, 134&#x2013;141</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6981003</ArticleId><ArticleId IdType="pubmed">31505072</ArticleId></ArticleIdList></Reference><Reference><Citation>Fuji RN et al. (2015) Effect of selective LRRK2 kinase inhibition on nonhuman primate lung. Sci. Transl. Med 7, 273ra15</Citation><ArticleIdList><ArticleId IdType="pubmed">25653221</ArticleId></ArticleIdList></Reference><Reference><Citation>Hancock-Cerutti W et al. (2021) ER-lysosome lipid transfer protein VPS13C/PARK23 prevents aberrant mtDNA- dependent STING signaling. Bioarxiv DOI: 10.1101/2021.06.08.447593</Citation><ArticleIdList><ArticleId IdType="doi">10.1101/2021.06.08.447593</ArticleId></ArticleIdList></Reference><Reference><Citation>Kelly K and West AB (2020) Pharmacodynamic biomarkers for emerging LRRK2 therapeutics. Front. Neurosci 14, 1&#x2013;11</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7438883</ArticleId><ArticleId IdType="pubmed">32903744</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang S et al. (2020) Exosome markers of LRRK2 kinase inhibition. npj Parkinson&#x2019;s Disease 6, 32</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7666125</ArticleId><ArticleId IdType="pubmed">33298972</ArticleId></ArticleIdList></Reference><Reference><Citation>Ashmus RA et al. (2018) Fluorescence-quenched substrates for quantitative live cell imaging of glucocerebrosidase activity. Methods Enzymol. 598, 199&#x2013;215</Citation><ArticleIdList><ArticleId IdType="pubmed">29306435</ArticleId></ArticleIdList></Reference><Reference><Citation>Sidransky E et al. (2009) Multi-center analysis of glucocerebrosidase mutations in Parkinson disease. N. Engl. J. Med 361, 1651&#x2013;1661</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2856322</ArticleId><ArticleId IdType="pubmed">19846850</ArticleId></ArticleIdList></Reference><Reference><Citation>Alcalay RN et al. (2014) Comparison of Parkinson risk in Ashkenazi jewish Gaucher patients and GBA heterozygotes. JAMA Neurol. 71, 752&#x2013;757</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4082726</ArticleId><ArticleId IdType="pubmed">24756352</ArticleId></ArticleIdList></Reference><Reference><Citation>Healy DG et al. (2008) Phenotype, genotype, and worldwide genetic penetrance of LRRK2-associated Parkinson&#x2019;s disease: a case-control study. Lancet Neurol. 7, 583&#x2013;590</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2832754</ArticleId><ArticleId IdType="pubmed">18539534</ArticleId></ArticleIdList></Reference><Reference><Citation>Zimprich A et al. (2004) Mutations in LRRK2 cause autosomal-dominant parkinsonism with pleomorphic pathology. Neuron 44, 601&#x2013;607</Citation><ArticleIdList><ArticleId IdType="pubmed">15541309</ArticleId></ArticleIdList></Reference><Reference><Citation>Ramirez A et al. (2006) Hereditary parkinsonism with dementia is caused by mutations in ATP13A2, encoding a lysosomal type 5 P-type ATPase. Nat. Genet 38, 1184&#x2013;1191</Citation><ArticleIdList><ArticleId IdType="pubmed">16964263</ArticleId></ArticleIdList></Reference><Reference><Citation>Martin S et al. (2020) Mutated ATP10B increases Parkinson&#x2019;s disease risk by compromising lysosomal glucosylceramide export. Acta Neuropathol. 139, 1001&#x2013;1024</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7244618</ArticleId><ArticleId IdType="pubmed">32172343</ArticleId></ArticleIdList></Reference><Reference><Citation>Kumar N et al. (2018) VPS13A and VPS13C are lipid transport proteins differentially localized at ER contact sites. J. Cell Biol 217, 3625&#x2013;3639</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6168267</ArticleId><ArticleId IdType="pubmed">30093493</ArticleId></ArticleIdList></Reference><Reference><Citation>Darvish H et al. (2019) Identification of a large homozygous VPS13C deletion in a patient with early-onset parkinsonism. Mov. Disord 33, 1968&#x2013;1970</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6309582</ArticleId><ArticleId IdType="pubmed">30452786</ArticleId></ArticleIdList></Reference><Reference><Citation>Bussi C et al. (2018) Alpha-synuclein fibrils recruit TBK1 and OPTN to lysosomal damage sites and induce autophagy in microglial cells. J. Cell Sci 131, 1&#x2013;19</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6518333</ArticleId><ArticleId IdType="pubmed">30404831</ArticleId></ArticleIdList></Reference><Reference><Citation>Rosborough K et al. (2017) &#x3b1;-Synuclein and parkinsonism: updates and future perspectives. Curr. Neurol. Neurosci. Rep 17,</Citation><ArticleIdList><ArticleId IdType="pubmed">28324300</ArticleId></ArticleIdList></Reference><Reference><Citation>Su MY et al. (2021) Structural basis for the ARF GAP activity and specificity of the C9orf72 complex. Nat. Commun 12, 1&#x2013;8</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8213707</ArticleId><ArticleId IdType="pubmed">34145292</ArticleId></ArticleIdList></Reference><Reference><Citation>Tang D et al. (2020) Cryo-EM structure of C9ORF72&#x2013;SMCR8&#x2013;WDR41 reveals the role as a GAP for Rab8a and Rab11a. Proc. Natl. Acad. Sci. U. S. A 117, 9876&#x2013;9883</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7211967</ArticleId><ArticleId IdType="pubmed">32303654</ArticleId></ArticleIdList></Reference><Reference><Citation>Lindquist SG et al. (2008) Frontotemporal dementia linked to chromosome 3 (FTD-3) - current concepts and the detection of a previously unknown branch of the Danish FTD-3 family. Eur. J. Neurol 15, 667&#x2013;670</Citation><ArticleIdList><ArticleId IdType="pubmed">18484988</ArticleId></ArticleIdList></Reference><Reference><Citation>Skibinski G et al. (2005) Mutations in the endosomal ESCRTIII-complex subunit CHMP2B in frontotemporal dementia. Nat. Genet 37, 806&#x2013;808</Citation><ArticleIdList><ArticleId IdType="pubmed">16041373</ArticleId></ArticleIdList></Reference><Reference><Citation>Stagi Massimiliano et al. (2014) Lysosome size, motility and stress response regulated by fronto-temporal dementia modifier TMEM106B. Mol. Cell. Neurosci 61, 226&#x2013;240</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4145808</ArticleId><ArticleId IdType="pubmed">25066864</ArticleId></ArticleIdList></Reference><Reference><Citation>Schwenk BM et al. (2014) The FTLD risk factor TMEM106B and MAP6 control dendritic trafficking of lysosomes. EMBO J. 33, 450&#x2013;467</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3989627</ArticleId><ArticleId IdType="pubmed">24357581</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>